Published in Elife on August 13, 2015
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol (2016) 0.88
microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget (2016) 0.79
Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife (2016) 0.77
A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis. Cell Discov (2016) 0.75
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer (2017) 0.75
Overaccumulation of p53-mediated autophagy protects against betulinic acid-induced apoptotic cell death in colorectal cancer cells. Cell Death Dis (2017) 0.75
Blinded by the Light: The Growing Complexity of p53. Cell (2009) 17.75
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
Clinical implications of the p53 tumor-suppressor gene. N Engl J Med (1993) 7.29
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
The P53 pathway: what questions remain to be explored? Cell Death Differ (2006) 4.91
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol (2001) 2.61
PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics (2009) 2.07
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 1.77
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 1.76
Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell (2013) 1.72
The BAG proteins: a ubiquitous family of chaperone regulators. Cell Mol Life Sci (2008) 1.63
Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol (2003) 1.59
Tumour-associated mutant p53 drives the Warburg effect. Nat Commun (2013) 1.52
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
Regulation of the cytoplasmic quality control protein degradation pathway by BAG2. J Biol Chem (2005) 1.46
The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. J Neurosci (2009) 1.38
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J Clin Invest (2014) 1.33
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene (2013) 1.27
Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun (2013) 1.19
LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget (2014) 1.08
E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ (2014) 1.07
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun (2014) 1.06
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett (2013) 1.04
Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53. Cell Death Differ (2015) 0.88
Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ (2011) 0.87
Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. J Biol Chem (2004) 0.84
The BAG2 protein stabilises PINK1 by decreasing its ubiquitination. Biochem Biophys Res Commun (2013) 0.81
The BAG2 and BAG5 proteins inhibit the ubiquitination of pathogenic ataxin3-80Q. Int J Neurosci (2014) 0.80
Polo-like kinase 2: a new exploitable target to undermine mutant p53-dependent chemoresistance. Cell Cycle (2012) 0.76